Abstract Library

#3006 Teratoma with Malignant Transformation: A Case Report of a Neuroendocrine Tumor That Arises from the Bronchial Mucosa in a Mature Cystic Teratoma

Introduction: Mature cystic teratoma (MCT) is the most common type of germ cell tumor in the ovary. A malignant tumor that arises in a pre-existing mature teratoma is called teratoma with malignant transformation (TMT).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Espinola Benza M

Authors: Espinola Benza M, La Salvia A, Hernandez Sanchez L, Gallardo Gallego R, Suarez Pita D,

Keywords: Mature cystic teratoma, teratoma with malignant transformation, surgical resection,

#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors

Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Peiró I, Vercher-Conejero J, Suils-Ramón J, Hernández L, Teulé A,

Keywords: 68Ga-DOTATOC PET/CT, metastatic neuroendocrine tumors,

#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)

Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Jimenez-Fonseca P, Solis Hernandez M, Fernandez del Valle A, Garcia-Carbonero R, Matos I,

Keywords: PNET, sunitinib, dose-intensive, progression-free survival,

#1937 Clinical Features and Outcomes of Advanced PNETs Treated with Sunitinib: Data from CRIPNET-GETNE Study

Introduction: There are several effective drugs for advanced pancreatic neuroendocrine tumors (PNETs) but the right treatment sequence hasn’t been defined yet.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Solis-Hernandez M

Authors: Solis-Hernandez M, Calvo-Temprano D, Carmona-Bayonas A, García-Carbonero R, Custodio A,

Keywords: Sunitinib, targeted therapies,

#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study

Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Solis-Hernandez M, Carmona-Bayonas A, Calvo-Temprano D, Nuñez B, Custodio A,

Keywords: sunitinib, PNET, choi, recist,